TAK-615

Research use only, not for human use.

TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.

TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.(In Vitro):TAK-615 specifically binds to membranes expressing the human LPA1 receptor with estimated Kd high affinity of 1.7 ± 0.5 nM and Kd low affinity of 14.5 ± 12.1 nM. TAK-615 is only able to partically inhibit the LPA response (~40% at 10 μM with an IC50 of 23 ± 13 nM in β-arrestin assay; 60% at 10 μM, IC50 of 91 ± 30 nM in calcuim mobilisation assay).

TAK-615 specifically binds to membranes expressing the human LPA1 receptor with estimated Kd high affinity (KdHi) of 1.7±0.5?nM and Kd low affinity (KdLo) of 14.5±12.1?nM. TAK-615 is only able to partially inhibit the LPA response (~?40% at 10?μM with an IC50 of 23±13?nM in β-arrestin assay; 60% at 10?μM, IC50 of 91±30?nM in calcium mobilisation assay) .

——

——

GPCR/G Protein

LPA Receptor

Interleukin

——

——

1664335-55-0

419.44

C25H22FNO4

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (298.02 mM)

OC(=O)C1=CC=C(CN(CC2CC2)C(=O)C2=CC=C(OC3=CC=CC=C3F)C=C2)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years